TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
This Quarter Return
+0.75%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.44B
AUM Growth
+$2.44B
(-4%)
Cap. Flow
-$52.5M
Cap. Flow
% of AUM
-2.15%
Top 10 Holdings %
Top 10 Hldgs %
38.65%
Holding
187
New
10
Increased
35
Reduced
38
Closed
19
Top Buys
| 1 |
Johnson & Johnson
JNJ
|
$43.6M |
| 2 |
Humana
HUM
|
$23.9M |
| 3 |
Eli Lilly
LLY
|
$20.7M |
| 4 |
Illumina
ILMN
|
$18.9M |
| 5 |
Abbott
ABT
|
$15.8M |
Top Sells
| 1 |
McKesson
MCK
|
$43.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$23.3M |
| 3 |
UnitedHealth
UNH
|
$23M |
| 4 |
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
|
$21.7M |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$19.4M |
Sector Composition
| 1 | Healthcare | 96.9% |
| 2 | Real Estate | 1.86% |
| 3 | Industrials | 0.15% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Agilent Technologies
A
$35.7B
| $5.25M | 0.21% | 43,191 | – | – |
|
77
Xencor
XNCR
$580M
| $5.21M | 0.21% | 200,328 -36,668 | -15% | -$953K |
|
78
Arrowhead Research
ARWR
$3.05B
| $5.19M | 0.21% | 156,875 | – | – |
|
|
CERE
79
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.99M | 0.2% | 176,483 +88,310 | +100% | +$2.5M |
|
80
Medical Properties Trust
MPW
$2.7B
| $4.88M | 0.2% | 411,743 | – | – |
|
81
Sanofi
SNY
$121B
| $4.69M | 0.19% | 123,454 | – | – |
|
82
Design Therapeutics
DSGN
$315M
| $4.69M | 0.19% | 280,523 +172,109 | +159% | +$2.88M |
|
|
VECT
83
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $4.54M | 0.19% | 756,502 | – | – |
|
84
BioCryst Pharmaceuticals
BCRX
$1.74B
| $4.41M | 0.18% | 349,570 +72,136 | +26% | +$909K |
|
85
Smith & Nephew
SNN
$16.3B
| $4.22M | 0.17% | 181,710 | – | – |
|
|
CCXI
86
DELISTED
ChemoCentryx, Inc.
CCXI
| $4.04M | 0.17% | 78,197 | – | – |
|
87
Align Technology
ALGN
$10.3B
| $3.91M | 0.16% | 18,894 | – | – |
|
88
Ionis Pharmaceuticals
IONS
$6.79B
| $3.89M | 0.16% | 87,840 -87,840 | -50% | -$3.89M |
|
89
Arvinas
ARVN
$568M
| $3.83M | 0.16% | 85,997 | – | – |
|
|
RCM
90
DELISTED
R1 RCM Inc. Common Stock
RCM
| $3.75M | 0.15% | 202,351 | – | – |
|
91
Teva Pharmaceuticals
TEVA
$21.1B
| $3.71M | 0.15% | 459,651 | – | – |
|
92
Healthcare Realty
HR
$6.11B
| $3.64M | 0.15% | 174,686 +104,024 | +147% | +$2.17M |
|
93
Cytokinetics
CYTK
$4.23B
| $3.64M | 0.15% | 75,139 -44,759 | -37% | -$2.17M |
|
94
CRISPR Therapeutics
CRSP
$4.71B
| $3.6M | 0.15% | 55,080 | – | – |
|
95
Health Care Select Sector SPDR Fund
XLV
$33.9B
| $3.52M | 0.14% | 29,024 -84,206 | -74% | -$10.2M |
|
96
Healthpeak Properties
DOC
$12.5B
| $3.45M | 0.14% | 150,392 | – | – |
|
97
Merus
MRUS
$4.98B
| $3.39M | 0.14% | 169,207 +73,917 | +78% | +$1.48M |
|
98
Adaptive Biotechnologies
ADPT
$2.01B
| $3.01M | 0.12% | 422,281 +84,559 | +25% | +$602K |
|
99
iShares Biotechnology ETF
IBB
$5.6B
| $2.87M | 0.12% | +24,569 | New | +$2.87M |
|
100
Arcutis Biotherapeutics
ARQT
$1.86B
| $2.85M | 0.12% | 148,874 | – | – |
|